β¬21.86-0.25 (-1.13%)
Koninklijke Philips N.V.
Koninklijke Philips N.V. in the Healthcare sector is trading at β¬21.86 with a market capitalization of $22.8B. Wall Street consensus targets β¬27.00 (20 analysts), implying a +23.5% move over the next 12 months. The stock is currently near its 52-week low of β¬20.90, remaining 6.3% below its 200-day moving average. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (EUR) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | β¬4.34Bβ | β¬4.30Bβ | β¬5.10Bβ | β¬3.90Bβ | β¬4.36B |
| Gross Profit | β¬2.01Bβ | β¬1.91Bβ | β¬2.29Bβ | β¬1.77Bβ | β¬2.15B |
| Operating Income | β¬401.00Mβ | β¬330.00Mβ | β¬565.00Mβ | β¬242.00Mβ | β¬610.00M |
| Net Income | β¬240.00Mβ | β¬184.00Mβ | β¬395.00Mβ | β¬151.00Mβ | β¬384.00M |
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imagin...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.

iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.

PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.
European equities traded in the US as American depositary receipts were edging higher late Thursday